Source comparison
Melanotan-1 Be Cycled Like Other Research Compounds: Comparison
Growth Hormone Secretagogues (MK-677, GHRP-2) Suppression of endogenous GH pulsatility; ghrelin receptor desensitisation 8–12 weeks on, 4–8 weeks off No endocrine suppression; no receptor desensitisation MT-1 requires no washout for receptor or hormonal recove
This comparison does not assign a generated winner or score.
- Growth Hormone Secretagogues (MK-677, GHRP-2)
- Suppression of endogenous GH pulsatility; ghrelin receptor desensitisation
- 8–12 weeks on, 4–8 weeks off
- No endocrine suppression; no receptor desensitisation
- MT-1 requires no washout for receptor or hormonal recovery
- Beta-2 Agonists (Clenbuterol, Albuterol)
- Rapid beta-adrenergic receptor downregulation
- 2 weeks on, 2 weeks off (or continuous with ketotifen)
- MC1R remains fully responsive under continuous agonism
- Standard cycling rationale does not apply to melanocortin receptors
- SARMs (RAD-140, LGD-4033)
- HPG axis suppression; potential hepatotoxicity
- 8–12 weeks on, 4–8 weeks off + PCT
- No suppression of testosterone or gonadotropins
- MT-1 has no impact on reproductive hormone axis
- Melanotan-1 (Afamelanotide)
- Cumulative melanogenesis; no receptor tolerance
- Front-load 10–20 days, maintenance or cessation for months
- Effect persists 45–60 days after stopping
- Cycling is optional and protocol-dependent, not pharmacologically mandated